摘要
目的观察厄贝沙坦治疗早期2型糖尿病肾病的临床效果。方法确诊为早期2型DN患者90例,随机分成时照组(45例)和观察组(45例)。对照组予传统常规治疗,控制血糖、血压(降压药排除ACEI及或ARB类)、血脂观察组在对照组治疗的基础上加用或换用厄贝沙坦控制血压,3月后比较两组血压、血脂、血糖指标、尿微量白蛋白及血清胱抑素C的变化。结果两组在治疗前各项指标无明显差异,经过3个月的治疗,两组的血压,血糖(Glu、2hPG、HbA1c),血脂(HDL-C、TG、LDL-C),U-mAlb,CysC和血压较治疗前均有明显好转,差异有统计学意义(P<0.01);观察组的U-mAlb和CysC较对照组改善更明显(P<0.05)。结论厄贝沙坦治疗早期糖尿病肾病,能有效减少U-mAlb及改善CysC水平,可能时延缓早期糖尿痛肾脏病的进展有益。
Objective To observe clinical effects of Irbesartan in treatment of early type 2 diabetic nephropathy. Methods Ninety patients with early type 2 diabetic nephropathy were enrolled in the study, including 45 patients treated with conventional medication （control group ） and another 45 patients treated with irbesartan （observation group）. The blood sugar, renal function index, urine albumin, plasma cystatin C were measured 3 months after treatment. Results Compare to control group, observation group had better clinical effect and laboratory results; there were significant differences in blood sugar （ Glu, 2hPG and HbA1 c ） and blood lipid （ HDL-C, TG, LDL-C ） levels, blood pressure control and kidney functions （U-mAlb and cystatin C） between two groups （all P 〈 0.05 ）. Conclusion Irbesartan has better clinical effect than conventional medication in treatment of early type 2 diabetic nephropathy.
出处
《同济大学学报（医学版）》
CAS
2013年第5期98-101,共4页
Journal of Tongji University(Medical Science)
